Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Pavlos Msaouel, MD
CONTACT
Lead
M.D. Anderson Cancer Center
With
Primary Objectives To determine the objective response rate (ORR) at any time and disease control rate (DCR) through 18 weeks from treatment initiation, as assessed by independent reviewer per RECIST 1.1, of sacituzumab tirumotecan in participants with locally advanced or metastatic SMARCB1-deficient RMC who have progressed on at least one prior line of therapy. Secondary Objectives To determine the efficacy and safety of sacituzumab tirumotecan in participants with locally advanced or metastatic SMARCB1-deficient RMC who have progressed on at least one prior line of therapy. Efficacy will be measured by overall survival (OS), progression-free survival (PFS), and duration of response (DOR).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted